Doramectin (Dectomax)

Doramectin, marketed under the brand name Dectomax, is a macrocyclic lactone belonging to the avermectin subclass of endectocides. Originally developed and approved for use in cattle and swine, doramectin has gained significant traction in veterinary dermatology and parasitology as an extra-label treatment for a range of parasitic conditions in dogs. Its broad-spectrum activity against both internal nematode parasites and external arthropod parasites makes it a versatile tool in the veterinary arsenal, particularly for managing treatment-resistant or severe cases of parasitic skin disease that may not respond adequately to first-line therapies.

The pharmacological action of doramectin centers on its ability to bind selectively to glutamate-gated chloride ion channels found in the nerve and muscle cells of invertebrate organisms. This binding causes an influx of chloride ions into the cell, resulting in hyperpolarization of the cell membrane, paralysis of the parasite's neuromuscular system, and ultimately death of the organism. Doramectin also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels in invertebrates, further amplifying its paralytic effect. Because these specific chloride channel subtypes are not present in mammals in the same configuration, doramectin achieves selective toxicity against parasites while sparing the host under normal circumstances.

Doramectin is distinguished from other avermectins by its pharmacokinetic profile, which includes a notably long plasma half-life and sustained tissue concentrations following subcutaneous injection. This extended duration of activity means that therapeutic drug levels persist in the bloodstream and tissues for a prolonged period compared to related compounds such as ivermectin. The long half-life is attributable to doramectin's high lipophilicity and extensive distribution into body fat stores, from which the drug is slowly released back into circulation. This characteristic makes doramectin particularly well suited for conditions requiring sustained antiparasitic exposure, such as generalized demodicosis.

Despite its efficacy and favorable pharmacokinetic characteristics, doramectin use in dogs requires careful veterinary oversight because the drug is not specifically labeled for canine patients. All use in dogs is considered extra-label, meaning the prescribing veterinarian assumes responsibility for determining appropriate dosing, monitoring protocols, and patient selection criteria. The risk of toxicity in dogs carrying the MDR1 (ABCB1) gene mutation, which impairs the blood-brain barrier's ability to exclude avermectins from the central nervous system, represents the most significant safety concern associated with doramectin use in canine medicine. Breed-specific genetic screening and cautious dose escalation protocols are essential components of safe doramectin therapy in dogs.

The most prominent extra-label application of doramectin in canine medicine is the treatment of generalized demodicosis caused by Demodex canis mites. Generalized demodectic mange presents as widespread hair loss, skin inflammation, secondary bacterial infection, and significant discomfort, and it can be refractory to conventional treatments in some patients. Doramectin's prolonged tissue concentrations and potent miticidal activity make it effective against Demodex populations residing deep within hair follicles, where the mites complete their entire life cycle. Treatment protocols for generalized demodicosis typically involve weekly subcutaneous injections continued until multiple consecutive negative skin scrapings confirm parasitological cure, a process that often spans several months.

Sarcoptic mange, caused by the burrowing mite Sarcoptes scabiei var. canis, responds well to doramectin therapy. This intensely pruritic condition involves mites tunneling into the superficial layers of the skin, causing severe itching, crusting, hair loss, and secondary skin infections. Doramectin administered as a series of subcutaneous injections at prescribed intervals effectively eliminates sarcoptic mite populations. The drug's systemic distribution ensures that mites are exposed to lethal concentrations regardless of their location within the skin, and the extended half-life provides continued protection during the treatment period, reducing the likelihood of reinfestation from environmental sources.

Doramectin has demonstrated efficacy against a variety of other ectoparasites affecting dogs, including ear mites (Otodectes cynanotis), nasal mites (Pneumonyssoides caninum), and certain tick and louse species. Ear mite infestations cause intense irritation of the ear canal, excessive wax production, and secondary otitis, and systemic doramectin treatment can resolve these infestations without the need for repeated topical ear treatments that many dogs resist. Nasal mite infestations, which cause chronic sneezing, nasal discharge, and respiratory discomfort, are also responsive to doramectin therapy, providing relief for a condition that can otherwise be difficult to treat effectively.

Gastrointestinal nematode infections represent another category of parasitic disease addressable with doramectin, though this application is less common in dogs given the availability of numerous labeled oral anthelmintics. Doramectin is active against a range of roundworm species including hookworms and roundworms that commonly infect the canine gastrointestinal tract. In cases where oral medication administration is difficult or where concurrent treatment of both ecto- and endoparasites is desired, doramectin offers the convenience of addressing multiple parasite classes with a single injectable drug.

Some veterinary practitioners have utilized doramectin as part of heartworm prevention protocols, though this represents an off-label application that requires careful dosing and monitoring. The drug's activity against Dirofilaria immitis microfilariae and developing larval stages can provide protection against heartworm infection when administered at appropriate intervals. However, the narrow margin between effective microfilaricidal doses and potentially toxic doses in MDR1-affected breeds makes this application one that requires thorough understanding of the individual patient's genetic background and close veterinary supervision throughout the prevention program.

Doramectin dosing in dogs is entirely determined by the prescribing veterinarian on an extra-label basis, as no canine-specific label dosing exists. The injectable formulation designed for livestock (10 mg/mL concentration) is the preparation most commonly adapted for canine use, and precise dosing requires careful calculation based on the individual dog's body weight and the specific condition being treated. Because of the significant risk of toxicity in genetically susceptible individuals, many veterinary dermatologists advocate for a gradual dose escalation protocol when initiating doramectin therapy, beginning at a fraction of the target dose and increasing incrementally while monitoring for adverse neurological signs.

For the treatment of generalized demodicosis, the most widely referenced dosing protocol involves subcutaneous injection at approximately 600 micrograms per kilogram of body weight administered at weekly intervals. Some protocols begin at a substantially lower dose, such as 100 micrograms per kilogram, and increase by 100 microgram increments each week until the full therapeutic dose is reached, provided the patient shows no signs of neurotoxicity during escalation. This cautious approach allows early identification of dogs with unrecognized MDR1 sensitivity before they receive potentially dangerous full doses of the medication.

Sarcoptic mange treatment protocols typically employ similar dosing to demodicosis protocols, with subcutaneous injections administered at weekly or biweekly intervals for a defined treatment course. Most dogs with sarcoptic mange show significant clinical improvement within two to three treatments, though additional injections may be prescribed to ensure complete elimination of the mite population and to prevent relapse. The veterinarian determines the number of treatments based on clinical response, resolution of pruritus, and results of follow-up skin scrapings or other diagnostic assessments.

The subcutaneous injection should be administered using appropriate technique to ensure accurate dosing and minimize injection site reactions. The injectable solution should be at room temperature before administration, and the injection site should be clean. Common injection sites include the loose skin over the shoulder blades or the lateral thorax. Because the livestock formulation volume may be very small for toy and small breed dogs, precise measurement using tuberculin or insulin syringes is necessary to avoid dosing errors that could result in either therapeutic failure from underdosing or toxicity from overdosing.

Treatment duration varies substantially depending on the condition being addressed. Sarcoptic mange may resolve with two to four weekly treatments, while generalized demodicosis often requires months of weekly injections continued until the dog achieves two to three consecutive monthly negative skin scrapings after clinical resolution. Premature discontinuation of therapy for demodicosis is a common cause of relapse, and owners must understand the commitment required for successful treatment. The veterinarian will establish clear criteria for treatment completion based on both clinical and parasitological endpoints.

Doramectin is generally well tolerated in dogs that do not carry the MDR1 gene mutation, and many patients complete full treatment courses without experiencing significant adverse effects. The most commonly reported minor side effects include transient pain or swelling at the injection site, mild lethargy for twelve to twenty-four hours following injection, decreased appetite on the day of treatment, and occasional soft stool. These effects are typically self-limiting and do not necessitate discontinuation of therapy. Owners should be informed that mild post-injection lethargy is expected and should resolve within a day.

The most serious potential adverse effect of doramectin in dogs is neurotoxicity, which occurs when the drug crosses the blood-brain barrier in sufficient concentrations to affect mammalian GABA receptors in the central nervous system. In dogs with normal P-glycoprotein function encoded by the MDR1 gene, the blood-brain barrier effectively excludes doramectin from the brain, maintaining the drug's selective toxicity against parasites. However, in dogs homozygous or heterozygous for the MDR1 mutation, this protective barrier is compromised, allowing doramectin to accumulate in cerebrospinal fluid and brain tissue at concentrations sufficient to produce neurological signs ranging from mild to life-threatening.

Neurological signs of doramectin toxicity follow a recognizable progression that begins with subtle changes and can advance to severe manifestations if exposure continues. Early signs include mydriasis (dilated pupils), mild ataxia, excessive salivation, and apparent disorientation. As toxicity progresses, dogs may develop more pronounced ataxia, tremors, apparent blindness, inability to stand, obtundation, and eventually stupor or coma. Seizure activity can occur in severe cases. The onset of neurological signs may be delayed by hours to days following injection due to the drug's slow distribution kinetics, meaning that dogs must be monitored closely not only immediately after injection but for several days thereafter.

Gastrointestinal side effects including vomiting, diarrhea, and anorexia occur occasionally and may represent either direct drug effects or reactions to the death of large numbers of parasites releasing inflammatory mediators and antigenic material. When treating heavy parasite burdens, the die-off of organisms can itself cause inflammatory reactions that produce clinical signs distinct from direct drug toxicity. Supportive care including antiemetics and fluid therapy may be indicated for dogs experiencing significant gastrointestinal disturbance during treatment.

Allergic or hypersensitivity reactions to doramectin are uncommon but have been reported. Signs may include facial swelling, urticaria, difficulty breathing, and in rare cases anaphylaxis. Dogs with known sensitivity to other macrocyclic lactones should be treated with particular caution, as cross-reactivity between members of this drug class is possible. Any signs of allergic reaction following doramectin injection warrant immediate veterinary attention and likely preclude further use of the drug in that patient.

Doramectin interacts significantly with other medications that are substrates, inhibitors, or inducers of the P-glycoprotein transport system encoded by the MDR1 (ABCB1) gene. P-glycoprotein functions as an efflux pump at the blood-brain barrier, intestinal epithelium, and other biological barriers, actively transporting certain drug molecules out of protected tissue compartments. Medications that inhibit P-glycoprotein function can effectively replicate the consequences of the MDR1 mutation by reducing the blood-brain barrier's capacity to exclude doramectin from the central nervous system, thereby increasing the risk of neurotoxicity even in dogs with normal genotypes.

Known P-glycoprotein inhibitors that should be used with extreme caution or avoided in dogs receiving doramectin include ketoconazole, itraconazole, cyclosporine, erythromycin, tamoxifen, verapamil, and spinosad. Ketoconazole and itraconazole are particularly relevant because antifungal therapy is frequently prescribed concurrently for dogs with demodicosis complicated by secondary fungal skin infections. The combination of doramectin with these azole antifungals substantially increases the risk of avermectin toxicity and should either be avoided entirely or managed with dose reductions and heightened monitoring under strict veterinary supervision.

Concurrent administration of doramectin with other macrocyclic lactone compounds such as ivermectin, milbemycin, moxidectin, or selamectin poses a risk of additive or synergistic neurotoxicity. Dogs receiving doramectin for mange treatment should not simultaneously receive heartworm preventatives containing these drugs unless specifically directed by the veterinarian, who will account for the total macrocyclic lactone exposure. In many cases, veterinarians will suspend monthly heartworm prevention during doramectin treatment for demodicosis, as the doramectin itself provides activity against heartworm larvae at therapeutic doses.

Benzodiazepines and other GABAergic drugs may have enhanced central nervous system depressant effects when combined with doramectin, as both drug classes ultimately affect inhibitory neurotransmission. While benzodiazepines are sometimes used therapeutically to manage early signs of avermectin toxicity, their concurrent use at full therapeutic doses could theoretically potentiate sedation. Veterinarians managing doramectin toxicity cases with supportive benzodiazepine therapy carefully titrate doses to achieve the desired protective effect without excessive central nervous system depression.

Owners should provide the prescribing veterinarian with a complete list of all medications, supplements, and flea and tick preventatives their dog receives before beginning doramectin therapy. Even over-the-counter products and herbal supplements may have P-glycoprotein inhibitory properties or other interactions that could affect doramectin safety. The veterinarian will assess the complete medication profile and make adjustments as necessary to minimize interaction risks throughout the treatment course.

The MDR1 (multidrug resistance 1) gene, now formally designated ABCB1, encodes the P-glycoprotein efflux transporter that plays a critical role in maintaining the blood-brain barrier's integrity against lipophilic drugs including all members of the macrocyclic lactone class. Dogs homozygous for the MDR1 mutation (mutant/mutant genotype) lack functional P-glycoprotein at the blood-brain barrier and are at severe risk of doramectin neurotoxicity at standard therapeutic doses. Dogs heterozygous for the mutation (mutant/normal genotype) have intermediate P-glycoprotein function and may tolerate reduced doses but remain at elevated risk compared to normal dogs.

Breeds with the highest prevalence of the MDR1 mutation include Collies, in which approximately seventy percent of individuals carry at least one copy of the mutant allele, along with Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, English Shepherds, German Shepherds, Longhaired Whippets, Silken Windhounds, McNabs, and mixed-breed dogs with herding breed ancestry. The mutation has also been identified at lower frequencies in breeds not traditionally classified as herding dogs, meaning that breed identification alone is insufficient for determining an individual dog's risk. Genetic testing through commercially available cheek swab or blood sample assays provides definitive determination of MDR1 genotype and is strongly recommended before initiating doramectin therapy in any dog.

For dogs confirmed as MDR1 normal (normal/normal genotype), doramectin can be administered at standard extra-label doses with routine monitoring and reasonable confidence in safety. For heterozygous dogs (mutant/normal), some clinicians may elect to use doramectin at reduced doses with more cautious escalation schedules and closer monitoring, though many dermatologists prefer to select alternative treatment options entirely for these patients. For homozygous mutant dogs (mutant/mutant), doramectin is contraindicated, and alternative therapies for mange and other parasitic conditions must be selected from drug classes not affected by P-glycoprotein transport.

Genetic testing should ideally be completed and results obtained before the first dose of doramectin is administered. If testing results are pending and treatment is clinically urgent, the veterinarian may initiate therapy at a very low dose with extremely cautious escalation, but this approach carries inherent risk and should only be pursued when the clinical severity of the parasitic disease justifies the potential for adverse events. Some veterinary dermatology referral centers maintain in-house rapid MDR1 testing capabilities that allow same-day results, facilitating timely treatment decisions for patients with severe demodicosis or other urgent parasitic conditions.

Beyond MDR1 considerations, very young puppies and geriatric dogs may exhibit increased sensitivity to doramectin due to immature or compromised blood-brain barrier function, respectively. Neonatal puppies have incompletely developed P-glycoprotein expression, and elderly dogs may have age-related deterioration in barrier function. These patient populations require additional caution in dosing decisions and monitoring intensity even when MDR1 testing indicates a normal genotype.

The absolute contraindication for doramectin use is confirmed MDR1 homozygous mutant (mutant/mutant) genotype, as these dogs cannot safely tolerate standard therapeutic doses of any avermectin-class drug. Administration of doramectin to homozygous MDR1-mutant dogs at doses used for mange treatment is likely to produce severe, potentially fatal neurotoxicity. This contraindication extends to dogs of breeds with known high MDR1 mutation prevalence when genetic testing has not been performed, as the risk of encountering a homozygous mutant individual is unacceptably high in these populations.

Doramectin should not be administered to dogs with known hypersensitivity to doramectin or other macrocyclic lactone compounds including ivermectin, milbemycin, moxidectin, selamectin, or eprinomectin. Cross-reactivity within the macrocyclic lactone class means that a dog that has experienced an adverse reaction to one member of this drug family may react similarly to others. Previous adverse neurological events associated with any avermectin or milbemycin compound should be considered a strong relative contraindication to doramectin use.

Dogs with heartworm disease require careful evaluation before receiving doramectin, as the drug's microfilaricidal activity can cause rapid die-off of circulating Dirofilaria immitis microfilariae, leading to potentially severe anaphylactoid reactions. The simultaneous death of large numbers of microfilariae releases inflammatory mediators, parasite antigens, and cellular debris into the bloodstream, which can trigger circulatory shock, respiratory distress, and disseminated intravascular coagulation. Heartworm testing should be performed before initiating doramectin therapy, and positive dogs should be managed with appropriate adulticidal and microfilaricidal protocols rather than receiving doramectin at full antiparasitic doses.

Pregnancy and lactation represent relative contraindications for doramectin use in dogs. While reproductive toxicity studies in the target livestock species have not demonstrated significant teratogenic effects at therapeutic doses, the safety of doramectin in pregnant and lactating dogs has not been specifically established. The drug's high lipophilicity and prolonged tissue residence raise theoretical concerns about fetal exposure and excretion in milk. Veterinarians generally recommend postponing elective doramectin treatment until after whelping and weaning unless the severity of the parasitic condition necessitates treatment during pregnancy.

Dogs with pre-existing neurological conditions, hepatic insufficiency, or renal compromise require additional precaution when doramectin is considered. Liver disease may impair doramectin metabolism, prolonging drug exposure and increasing the risk of accumulation to toxic levels. Renal dysfunction may similarly affect drug clearance, though doramectin is primarily eliminated through hepatic metabolism and biliary excretion. Neurological conditions affecting the blood-brain barrier integrity, including recent head trauma, brain tumors, or inflammatory central nervous system disease, could theoretically facilitate doramectin entry into the brain even in MDR1-normal dogs.

The commercial Dectomax injectable solution should be stored at controlled room temperature between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit), protected from light, and kept in its original packaging until use. The solution should not be frozen, as freezing may alter the drug's physical properties and potentially affect potency or tolerability upon injection. Once the multidose vial has been punctured, the remaining solution should be used within the timeframe specified by the manufacturer, and the vial should be stored with the rubber stopper clean and intact to prevent contamination.

Because doramectin is formulated as a livestock product in relatively large multidose vials, veterinary practices treating dogs must exercise careful aseptic technique when withdrawing doses from these vials to prevent bacterial contamination of the remaining solution. Each withdrawal should be performed using a new sterile needle and syringe, and the vial stopper should be swabbed with alcohol before each puncture. Small animal practitioners may find it practical to draw up multiple doses into individual syringes at one time for use during a single clinic day, provided these pre-drawn syringes are properly labeled, stored appropriately, and used within a short timeframe.

Accurate dose measurement is critical given the potency of the concentrated injectable solution and the small volumes required for canine patients, particularly those of small body size. A typical ten-kilogram dog receiving 600 micrograms per kilogram would require only 0.6 milliliters of the 10 mg/mL solution. For very small dogs, the required volume may be a fraction of a milliliter, necessitating the use of tuberculin syringes or insulin syringes graduated in hundredths of a milliliter to achieve acceptable dosing precision. Dosing errors due to imprecise volume measurement represent a preventable source of either therapeutic failure or toxicity.

Owners do not typically handle or store doramectin at home, as administration is performed by veterinary staff at scheduled clinic visits. However, owners should be aware that the drug is a potent parasiticide and that accidental human exposure through needlestick injury or skin contact should be reported to a physician. The product safety data sheet should be available at the veterinary practice for reference in the event of accidental human exposure. Doramectin is toxic to aquatic organisms and should be disposed of according to local regulations governing pharmaceutical waste rather than being discarded in household trash or flushed down drains.

Dogs receiving doramectin therapy require systematic clinical monitoring to assess both therapeutic response and potential adverse effects throughout the treatment course. The monitoring schedule typically involves veterinary examination before each weekly injection during the initial dose escalation phase, with possible extension to biweekly or monthly visits once the full therapeutic dose has been established and tolerated without adverse effects. Each visit should include a focused neurological assessment evaluating pupil size and responsiveness, gait and coordination, mentation, cranial nerve function, and proprioceptive awareness.

For dogs being treated for demodicosis, parasitological monitoring through deep skin scrapings is an essential component of the follow-up protocol. Skin scrapings should be performed at regular intervals, typically monthly once the dog is on a stable treatment dose, to track the progression from positive scrapings with live mites through decreasing mite counts to consecutive negative scrapings. The treatment endpoint for generalized demodicosis is generally defined as two to three consecutive monthly skin scrapings that fail to detect any mites, whether live or dead, followed by continued observation for relapse during a post-treatment monitoring period.

Owners play a crucial role in monitoring for early signs of doramectin toxicity between veterinary visits and should receive detailed instructions on what to observe and when to seek immediate veterinary attention. Warning signs that should prompt urgent contact with the veterinarian include any change in pupil size, stumbling or uncoordinated movement, excessive drooling, apparent visual impairment, trembling, unusual lethargy beyond what was experienced with previous injections, vomiting, or any behavioral change that seems abnormal for the individual dog. Early recognition of toxicity signs allows prompt intervention and generally results in better outcomes than delayed presentation.

Baseline and periodic bloodwork may be recommended depending on the anticipated duration of therapy and the individual patient's health status. A pre-treatment complete blood count and serum chemistry panel establishes baseline values for hepatic and renal function parameters that may be relevant if toxicity or illness develops during treatment. For dogs receiving extended treatment courses spanning months, periodic reassessment of organ function helps ensure that the dog's capacity to metabolize and eliminate the drug remains adequate throughout the treatment period.

Post-treatment monitoring following completion of a demodicosis treatment course should continue for at least twelve months, as relapse can occur even after achieving consecutive negative skin scrapings. Monthly to bimonthly veterinary examinations with skin scrapings during this observation period allow early detection of mite population resurgence before clinical disease recurs. Dogs that relapse after an apparently successful treatment course may require retreatment with doramectin or transition to an alternative therapeutic approach, and the recurrence pattern provides important information for long-term management planning.

Doramectin toxicity is a veterinary emergency that requires immediate professional intervention, as the condition can progress rapidly from mild neurological signs to life-threatening central nervous system depression. There is no specific antidote for avermectin toxicity, and treatment is primarily supportive, aimed at maintaining vital functions while the drug is gradually metabolized and eliminated from the body. Given doramectin's exceptionally long half-life, clinical recovery from toxicity may require days to weeks of intensive supportive care depending on the severity of clinical signs and the magnitude of the dose received.

Initial emergency assessment of a dog presenting with suspected doramectin toxicity should include evaluation of neurological status, cardiovascular function, respiratory adequacy, and body temperature. Dogs with severe toxicity may present with profound obtundation or coma, requiring immediate airway management and ventilatory support. Hypothermia is common in severely affected dogs due to loss of thermoregulatory function and should be addressed with active warming. Intravenous catheter placement and fluid therapy initiation are early priorities to support cardiovascular function and facilitate drug elimination through hepatic metabolism.

Intravenous lipid emulsion (ILE) therapy has emerged as a valuable treatment modality for avermectin toxicity in dogs and represents the most significant advance in managing these cases. The mechanism of ILE therapy involves providing a lipid compartment in the bloodstream that sequesters the highly lipophilic avermectin molecules, effectively reducing the free drug concentration available to interact with central nervous system receptors. Published case reports and case series have documented dramatic improvement in dogs with severe avermectin toxicity following ILE administration, with some dogs showing clinical improvement within hours of infusion. The standard protocol involves an initial bolus followed by a continuous rate infusion, with the specific dosing determined by the treating veterinarian based on the patient's clinical status.

Nutritional support becomes necessary for dogs experiencing prolonged recovery from doramectin toxicity, as severely affected patients may be unable to eat or drink voluntarily for days. Enteral feeding through nasogastric or esophagostomy tube placement provides nutritional support while minimizing the risks associated with prolonged anorexia. Parenteral nutrition may be considered for patients that cannot tolerate enteral feeding. Careful management of hydration, electrolyte balance, glucose homeostasis, and caloric needs is essential throughout the recovery period to prevent secondary complications that could compromise the outcome.

Owners of dogs recovering from doramectin toxicity should anticipate a potentially extended recovery period and should receive honest prognostic communication from the veterinary team. Dogs that experienced mild to moderate neurological signs generally recover fully within a few days with appropriate supportive care. Severely affected dogs may require one to four weeks for complete recovery, and some patients may have persistent subtle neurological deficits. The prognosis for survival is generally favorable when toxicity is recognized early and intensive supportive care including ILE therapy is initiated promptly, though fatalities can occur with massive overdoses or delayed treatment in severely affected individuals.